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1015-9584/Copyright ª 2013, Asian Su
NC-ND license (http://creativecommoSummary Extracranial and meningeal seeding of glioblastoma multiforme is rare. We report
herein a case of glioblastoma in a 41-year-old man who underwent surgical resection, concom-
itant chemoradiotherapy (CCRT) and seven courses of adjuvant chemotherapy with temozolo-
mide. The patient then complained of intermittent severe lower back pain and gait
disturbance. Imaging studies demonstrated that although the intracranial residual tumors were
well-controlled by the treatment, meningeal seeding involving the brainstem and spinal cord
was present. The patient died 2 months after the diagnosis of spinal seeding. This case illus-
trates the need for consideration of extracranial metastasis if a patient is symptomatic, even
if the intracranial tumor appears responsive to treatment. We suggested that the prophylactic
craniospinal irradiation may be considered in patients at high risk of meningeal seeding imme-
diately after surgery.
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Glioblastoma multiforme (GBM) is the most malignant pri-
mary brain tumor, for which current standard treatment
includes surgical resection, concomitant chemo-
radiotherapy with temozolomide (TMZ), and adjuvant
chemotherapy for 6e12 cycles. Extracranial seeding of GBM
is very rare, especially when the tumor is well-controlled at
the primary site. Whether temozolomide chemotherapy can
prevent meningeal seeding is not conclusive. We report
herein the case of a patient who responded to standard
treatment but was diagnosed with meningeal seeding.2. Case report
A 41-year-old male patient with an unremarkable past
medical history presented with blurred vision, intermittent
headache, and low-grade fever and was admitted to our
hospital. Neurological examination revealed homonymous
right hemianopsia. Hemogram, blood chemistry, and urine
laboratory data were normal, with the exception of
leukocytosis [White blood cell (WBC), 12.4  109/L]. Head
computed tomography (CT) and magnetic resonance imag-
ing (MRI) demonstrated a well-enhanced mass lesion in the
left parieto-occipital lobe with marked perifocal brain
edema, which compressed lateral ventricles, and another
smaller lesion located anterior to the main mass (Fig. 1A
and B). The patient underwent a craniotomy and partialFigure 1 Gadolinium-enhanced axial T1-weighted MRI showing th
month adjuvant chemotherapy (C, D), and after spinal seeding hadtumor excision, and the satellite lesion was left untouched.
Pathological examination of the tumor identified it as GBM.
The methylation status of the O6-methylguanine-DNA
methyltransferase (MGMT) promoter in the GBM sample was
analyzed using methylation-specific PCR, and the MGMT
promoter was found to be unmethylated.
After the operation, the patient recovered uneventfully,
with the exception of the persistence of a visual field defect.
Two weeks after the surgery, he received concomitant che-
moradiotherapy (CCRT) with TMZ (75 mg/m2/day) and
external beam X-ray irradiation therapy (60 Gy/2 Gy/frac-
tion), which was tolerated well. Adjuvant chemotherapy
with TMZ (200 mg/m2/day) for 5 days every 4 weeks was
subsequently administered. MRI was performed at 3-month
intervals and showed no evidence of tumor progression,
and the patient returned to work as an engineer 3 months
after diagnosis. After the 7th cycle of adjuvant chemo-
therapy, he complained of intermittent severe lower back
pain and gait disturbance. Neurological examination
revealed hyperreflexia of the bilateral knee and ankle jerks,
and positive cerebellar signs. There was no urinary retention
or incontinence. Subsequent MRI revealed no progression of
the intracranial tumors, but marked meningeal seeding
involving the entire spinal cord and brainstem was observed
(Figs. 2 and 3). Lumbar puncture was performed and the
cerebrospinal fluid (CSF) cytology demonstrated atypical
neoplastic cells with enlarged nuclei and abundant cyto-
plasm (Fig. 4). CSF examination revealed mild pleiocytosis
(21 WBCs/mm3 with a lymphocyte:monocyte:neutrophile intracranial tumors prior to surgery (A, B), after CCRT and 5-
been diagnosed (E, F).
Figure 2 Pre- (A, C) and postcontrast (B, D) T1-weighted MR images of the thoracic spine showing enhanced subarachnoid (arrow)
and intramedullary lesions.
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level (623.9 mg/dL) and decreased glucose concentration
(CSF 28mg/dL; serum105mg/dL).Whole-spine radiotherapy
was planned with 1.5 Gy/fraction to a total of 30 Gy; how-
ever, only a total of 16.5 Gy was administered because the
patient presented with severe vertigo, confusion, disorien-
tation, and hallucination. The radiotherapy did not effec-
tively alleviate his pain, and his family refused further
treatment; the patient died 2 months after diagnosis of spi-
nal seeding.
3. Discussion
Symptomatic CSF seeding of intracranial GBM is rare, ac-
counting for only 2% of cases in a study of 600 patients.1
The same study showed that CSF seeding occurred
mostly in the late stage of GBM, with a mean duration of
14.1 months after diagnosis of the primary tumor. CCRT
and adjuvant TMZ has significantly prolonged the survival
of GBM patients in recent years, although whether or not
lengthier survival may lead to a greater chance of CSF
seeding is still unknown. In the rare cases of spinal
seeding reported, the time point of diagnosis was usually
after intracranial tumor recurrence or progression, and
most of these patients died from progression of the
intracranial disease.13 However, our case demonstrated
that CSF seeding can occur when the primary tumor iswell-controlled by radiotherapy and chemotherapy. In
cases of tumors in close contact with CSF, young patients,
or in which the ventricles were opened during surgery,
there may be greater risk of metastasis into the CSF.1 In
the series of Bryan (1974),4 57 cases of GBM with intra-
ventricular or spinal seeding were diagnosed at post
mortem, and all of these tumors directly destroyed the
ependymal lining and invaded the ventricles. Prophylactic
craniospinal irradiation may be considered in patients at
high risk of seeding.
The thoracic and lumbosacral spine are the most com-
mon sites for spinal seeding.5 The seeding of tumor cells
usually presents as a solid tumor rather than a layer of
tumor coating the spinal cord or brainstem.2,3 The common
presentations of spinal seeding include back pain, radicular
pain, paraparesis or quadraparesis, and urinary retention/
incontinence.6 If CSF seeding involves the brainstem,
changes in mental state may be observed.7
CSF study is a useful tool if patients of GBM develop
atypical symptoms during treatment or in the follow-up
period.8 The CSF finding of neoplastic cells or elevated
protein levels may indicate MRI study of the whole spine
with gadolinium contrast in order to evaluate the possibility
and extent of spinal seeding.
Although the unmethylated promoter of MGMT in the
primary tumor of our patient was not predictive of a good
outcome,9 the tumor was not in progression after CCRT and
Figure 3 Postcontrast T1-weighted MR images of the cervical (A) and lumbar spine (B) demonstrating subarachnoid and lep-
tomeningeal enhancement (arrow). Postcontrast axial T-weighted MR images of the brain taken upon patient presentation of back
pain, showing an enhanced lesion (arrowhead) surrounding the medulla oblongata (D), which can be compared with images ob-
tained after 5-month adjuvant chemotherapy (C).
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the tumor cells in the CSF was not determined owing to the
insufficient number of tumor cells collected. CSF seeding
has never previously been reported in cases in which the
primary tumor appears to be controlled with radiotherapy
and chemotherapy with no regrowth. A case of spinal cord
intramedullary metastasis of GBM has been reported, but
the patient had received only radiotherapy.6 A difference in
the level of expression of glial fibrillary acidic protein
(GFAP) between the primary site of the tumor and the
disseminated tumor indicates the possibility of geneticFigure 4 CSF cytology. A few atypical cells are apparent,
with enlarged round to oval nuclei and abundant cytoplasm.changes during the course of treatment,8 and these genetic
or epigenetic alterations may explain why the metastatic
tumors are refractory to adjuvant temozolomide
chemotherapy.
Survival after a diagnosis of leptomeningeal metastasis
has been reported to be around 2e4 months.1,8,10 Radio-
therapy has been reported to temporarily control back pain
caused by spinal seeding, but was not found to be of benefit
in terms of survival.1 To date, there is still no standard
therapy for recurrent GBM after failure of radiotherapy and
alkylator-based chemotherapy. For recurrent tumors, clin-
ical trials of some new regimens have demonstrated some
progression: A combination of anti-VEGF and topoisomerase
1 inhibitor in a Phase II clinical trial improved the prognosis
for patients of recurrent GBM,11 and other clinical trials
focusing on single-agent or multi-agent chemotherapy have
demonstrated some activity.1216 In our patient, adminis-
tration of second-line chemotherapy with bevacizumab and
irinotecan had been considered after the completion of
whole-spine radiotherapy; however, the plan was cancelled
because of the rapid deterioration in the patient’s
condition.
This case illustrates the importance of considering the
possibility of CSF seeding when new symptoms occur even if
the supratentorial GBM is stable after radiotherapy and
chemotherapy. MRI should be used as an initial imaging
study to evaluate suspected spinal dissemination. Radio-
therapy and systemic or intrathecal second-line chemo-
therapy may help to alleviate the symptoms and prolong
survival. We suggested that the prophylactic craniospinal
irradiation may be considered in patients at high risk of
seeding immediately after surgery.
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